CA2131647A1 - Sustained Release Heterodisperse Hydrogel Systems for Insoluble Drugs - Google Patents
Sustained Release Heterodisperse Hydrogel Systems for Insoluble DrugsInfo
- Publication number
- CA2131647A1 CA2131647A1 CA2131647A CA2131647A CA2131647A1 CA 2131647 A1 CA2131647 A1 CA 2131647A1 CA 2131647 A CA2131647 A CA 2131647A CA 2131647 A CA2131647 A CA 2131647A CA 2131647 A1 CA2131647 A1 CA 2131647A1
- Authority
- CA
- Canada
- Prior art keywords
- sustained release
- insoluble drugs
- hydrogel systems
- hydrophobic polymer
- gelling agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
Abstract
A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic crosslinking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/118,924 | 1993-09-09 | ||
US08/118,924 US5455046A (en) | 1993-09-09 | 1993-09-09 | Sustained release heterodisperse hydrogel systems for insoluble drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2131647A1 true CA2131647A1 (en) | 1995-03-10 |
CA2131647C CA2131647C (en) | 1999-08-10 |
Family
ID=22381584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002131647A Expired - Lifetime CA2131647C (en) | 1993-09-09 | 1994-09-08 | Sustained release heterodisperse hydrogel systems for insoluble drugs |
Country Status (11)
Country | Link |
---|---|
US (6) | US5455046A (en) |
EP (2) | EP1101489B1 (en) |
JP (1) | JP4077886B2 (en) |
AT (2) | ATE207742T1 (en) |
CA (1) | CA2131647C (en) |
DE (3) | DE642785T1 (en) |
DK (1) | DK0642785T3 (en) |
ES (2) | ES2254274T3 (en) |
GR (1) | GR950300035T1 (en) |
IL (1) | IL110744A (en) |
PT (2) | PT1101489E (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689386B2 (en) | 1996-07-08 | 2004-02-10 | Penwest Pharmaceuticals Co. | Sustained release matrix for high-dose insoluble drugs |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
DK0797988T3 (en) | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogenic compositions and methods for their use |
US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US6183778B1 (en) | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
US5399358A (en) * | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
US5399362A (en) * | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
CN1131023C (en) * | 1994-04-25 | 2003-12-17 | 潘威斯脱药物公司 | Sustained release excipient |
NZ270439A (en) * | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US6540993B1 (en) * | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
GB9519363D0 (en) * | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
WO1997026865A1 (en) * | 1996-01-29 | 1997-07-31 | Edward Mendell Co., Inc. | Sustained release excipient |
AU770001B2 (en) * | 1996-04-18 | 2004-02-12 | Penwest Pharmaceutical Co. | Sustained release heterodisperse hydrogel systems - amorphous drugs |
AU737078C (en) * | 1996-05-24 | 2002-05-02 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
IN186245B (en) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
DE19747261A1 (en) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Single-chamber osmotic pharmaceutical release system |
US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6337091B1 (en) * | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
US20010038855A1 (en) * | 1998-06-05 | 2001-11-08 | Desjardin Michael A. | Dosage form for administering prescribed dose |
JP2002531491A (en) | 1998-12-11 | 2002-09-24 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | Sustained-release tablet containing hydrocolloid and cellulose ether |
US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
HUP0104472A3 (en) * | 1999-09-30 | 2002-12-28 | Penwest Pharmaceuticals Co Pat | Sustained release matrix systems for highly soluble drugs |
US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
USD432121S (en) * | 1999-12-13 | 2000-10-17 | E-Lead Electronics Co., Ltd. | Holder for a mobile telephone for an automobile |
US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
MXPA02006335A (en) | 1999-12-23 | 2002-12-13 | Pfizer Prod Inc | Hydrogeldriven layered drug dosage form. |
US7056531B1 (en) | 2000-05-04 | 2006-06-06 | Nature's Way Products, Inc. | Sustained release compositions for orally administered substances and methods |
US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
PT1296656E (en) * | 2000-06-27 | 2006-12-29 | Hoffmann La Roche | Method for preparing a composition |
US6720005B1 (en) | 2000-07-07 | 2004-04-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Coated, platform-generating tablet |
JP2004520088A (en) | 2000-08-15 | 2004-07-08 | サーモディックス,インコーポレイティド | Drug admixture matrix |
EP1322303A1 (en) * | 2000-10-03 | 2003-07-02 | Penwest Pharmaceuticals Co. | Delivery system for multi-pharmaceutical active materials at various release rates |
US6497901B1 (en) | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
ES2436523T3 (en) * | 2001-03-13 | 2014-01-02 | Endo Pharmaceuticals Inc. | Therapeutic dosage forms |
CN101129327A (en) * | 2001-04-20 | 2008-02-27 | 阿尔扎公司 | Micro-projection array having a beneficial agent containing coating |
EP3251722B1 (en) * | 2001-04-20 | 2020-06-17 | ALZA Corporation | Microprojection array having a beneficial agent containing coating and method of forming the coating thereon |
US9820982B2 (en) | 2001-07-06 | 2017-11-21 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US20030129234A1 (en) * | 2001-07-06 | 2003-07-10 | Penwest Pharmaceuticals Company | Methods of making sustained release formulations of oxymorphone |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US6703045B2 (en) | 2001-08-21 | 2004-03-09 | Council Of Scientific & Industrial Research | Composition and method for maintaining blood glucose level |
US20030091635A1 (en) * | 2001-09-26 | 2003-05-15 | Baichwal Anand R. | Opioid formulations having reduced potential for abuse |
US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
AU2003230805A1 (en) * | 2002-04-05 | 2003-10-27 | Penwest Pharmaceuticals Co. | Sustained release metoprolol formulations |
CA2494281A1 (en) * | 2002-08-02 | 2004-02-12 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
KR100548925B1 (en) * | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | Sustained release composition for oral administration of a drug |
US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
DK3241550T3 (en) * | 2002-11-22 | 2020-08-24 | Gruenenthal Gmbh | USE OF (1R, 2R) -3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL FOR THE TREATMENT OF INFLAMMATORY PAIN |
MXPA06003100A (en) * | 2003-09-19 | 2006-06-20 | Penwest Pharmaceuticals Co | Delayed released dosage forms. |
EP1663156A2 (en) * | 2003-09-19 | 2006-06-07 | Penwest Pharmaceuticals Company | Chronotherapeutic dosage forms |
US20070191319A1 (en) * | 2003-12-17 | 2007-08-16 | Pfizer Inc. | Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen |
US20060004076A1 (en) * | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
AU2005320547B2 (en) | 2004-12-27 | 2009-02-05 | Eisai R & D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
EP1912628A2 (en) * | 2005-06-29 | 2008-04-23 | Panacea Biotec Ltd. | Pharmaceutical sustained release compositions and processes thereof |
EP1743638A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Pharmaceutical formulations of substituted pyrazoline compounds |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
WO2007059372A2 (en) * | 2005-11-09 | 2007-05-24 | St. Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
US20080069889A1 (en) * | 2006-03-07 | 2008-03-20 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
JP4720620B2 (en) * | 2006-05-30 | 2011-07-13 | コニカミノルタビジネステクノロジーズ株式会社 | Curl correction device and image forming apparatus having the same |
US8124598B2 (en) * | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
US20110165236A1 (en) * | 2006-09-22 | 2011-07-07 | Biokey, Inc. | Controlled release hydrogel formulation |
US20080075785A1 (en) * | 2006-09-22 | 2008-03-27 | San-Laung Chow | Controlled release hydrogel formulation |
US20080085304A1 (en) * | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
US20080085305A1 (en) * | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations of oxymorphone |
US20080085303A1 (en) * | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations of oxymorphone and methods of use thereof |
MX2009007913A (en) * | 2007-01-25 | 2009-07-31 | Panacea Biotec Ltd | Modified release pharmaceutical composition and a process of making the same. |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
US20110207718A1 (en) | 2008-08-06 | 2011-08-25 | Gosforth Centre (Holdings) Pty Ltd. | Compositions and methods for treating psychiatric disorders |
AU2009289776A1 (en) | 2008-09-05 | 2010-03-11 | Grunenthal Gmbh | Pharmaceutical combination of 3- (3-Dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic |
US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
GB0817120D0 (en) * | 2008-09-19 | 2008-10-29 | Diurnal Ltd | Treatment of adrenal insufficiency |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
JP5433295B2 (en) * | 2009-05-01 | 2014-03-05 | 高田製薬株式会社 | Xanthan gum-coated water-soluble saccharide and compression-molded preparation |
AR077987A1 (en) | 2009-08-28 | 2011-10-05 | Gruenenthal Gmbh | PHARMACEUTICAL COMBINATION THAT INCLUDES 6-DIMETHYLAMINOMETIL-1- (3-METOXIFENIL) -CICLOHEXANO-1,3-DIOL OR 6-DIMETHYLAMINOMETIL-1- (3-HYDROXYPHENYL) -CICLOHEXANO-1,3-DIOL AND AN ANTIEPYLEPTIC |
WO2011157391A1 (en) | 2010-06-15 | 2011-12-22 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
EP2827839B1 (en) | 2012-03-20 | 2019-02-27 | Particle Dynamics International, LLC | Gelling agent-based dosage form |
US8912226B2 (en) | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
US9308196B2 (en) | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
US9345689B2 (en) | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
US20150133516A1 (en) | 2013-11-13 | 2015-05-14 | Brian K. Adams | Methods and Compositions for Treating ADHD |
AU2016288643A1 (en) | 2015-07-02 | 2018-02-22 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670827C3 (en) * | 1967-03-20 | 1974-10-24 | Bayer Ag, 5090 Leverkusen | 4- (2'-nitrophenyl) -2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine |
SU432703A3 (en) * | 1971-08-24 | 1974-06-15 | Фридрих Боссерт, Вульф Фатер, Курт Бауер | |
DE2714065A1 (en) * | 1977-03-30 | 1978-10-12 | Boehringer Mannheim Gmbh | INSTILLATION PREPARATION |
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
JPS5630485A (en) * | 1979-08-21 | 1981-03-27 | Sansho Kk | Heat insulation composition for heating and cooling |
DE3033919A1 (en) * | 1980-09-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | SOLID PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND METHOD FOR THE PRODUCTION THEREOF |
US5264446A (en) * | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
US4346709A (en) * | 1980-11-10 | 1982-08-31 | Alza Corporation | Drug delivery devices comprising erodible polymer and erosion rate modifier |
JPS5846019A (en) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | Nifedipine preparation with prolonged action |
JPS59101423A (en) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | Novel solid pharmaceutical preparation of nifedipine |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
DE3318649A1 (en) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | TWO-PHASE FORMULATION |
DE3320582A1 (en) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | METHODS OF PREPARATION WITH GLIQUIDONE AND METHOD FOR THE PRODUCTION THEREOF |
US4851229A (en) * | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
JPS60139688A (en) * | 1983-12-28 | 1985-07-24 | Tokyo Tanabe Co Ltd | Amorphous dihydropyridine powder pharmaceutical |
DE3400106A1 (en) * | 1984-01-04 | 1985-07-11 | Klaus-Dieter Dr. 3550 Marburg Bremecker | Pharmaceutical compositions with controlled release of medicinal substance |
AU4064285A (en) * | 1984-03-21 | 1985-10-11 | American Home Products Corporation | Sustained release pharmaceutical capsules |
HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
DE3438830A1 (en) * | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF |
DE3586713T2 (en) * | 1984-11-15 | 1993-05-13 | Hercon Lab | DEVICE FOR THE CONTROLLED DELIVERY OF DRUG ACTIVE SUBSTANCES. |
GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
IT1187751B (en) * | 1985-10-15 | 1987-12-23 | Eurand Spa | PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
SE8601624D0 (en) * | 1986-04-11 | 1986-04-11 | Haessle Ab | NEW PHARMACEUTICAL PREPARATIONS |
US4803076A (en) * | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
DE3636123A1 (en) * | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE |
ATE68704T1 (en) * | 1986-12-18 | 1991-11-15 | Bauer Kurt Heinz | NIFEDIPIN CONCENTRATE STABILIZED AGAINST LIGHT EFFECTS AND PROCESS FOR ITS PRODUCTION. |
IE59540B1 (en) * | 1987-01-09 | 1994-03-09 | Elan Corp | Sustained release capsule or tablet formulation |
US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
GB8705083D0 (en) * | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US5288500A (en) * | 1987-03-13 | 1994-02-22 | Benzon Pharma A/S | Oral composition containing particles comprising an active substance |
KR880012221A (en) * | 1987-04-13 | 1988-11-26 | 사노 가즈오 | Pharmaceutical compositions containing esters or amides as active ingredients |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
DE3720757A1 (en) * | 1987-06-24 | 1989-01-05 | Bayer Ag | DHP COAT TABLET |
FR2618073B1 (en) * | 1987-07-16 | 1990-09-07 | Pf Medicament | HYDROPHILIC MATRIX-TYPE TABLETS BASED ON SALBUTAMOL AND THEIR PREPARATION METHOD |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
GB8722306D0 (en) * | 1987-09-22 | 1987-10-28 | Aps Research Ltd | Sustained-release formulation |
SE8703881D0 (en) * | 1987-10-08 | 1987-10-08 | Haessle Ab | NEW PHARMACEUTICAL PREPARATION |
GB8723896D0 (en) * | 1987-10-12 | 1987-11-18 | Aps Research Ltd | Controlled-release formulation |
US5160734A (en) * | 1987-11-25 | 1992-11-03 | American Cyanamid Company | Sustained release delivery system for substituted dihydropyridine calcium channel blockers |
JP2670680B2 (en) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | Polylactic acid microspheres containing physiologically active substance and method for producing the same |
DE68915494T2 (en) * | 1988-03-09 | 1995-01-05 | Snow Brand Milk Products Co Ltd | PREPARATION WITH DELAYED RELEASE BY USING ALGINATES. |
US5211957A (en) * | 1988-03-25 | 1993-05-18 | Ciba-Geigy Corporation | Solid rapidly disintegrating dosage form |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
JP2528706B2 (en) * | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | Pharmaceutical composition of dihydropyridine compound |
US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
GB8903328D0 (en) * | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
HU203041B (en) * | 1989-03-14 | 1991-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5091190A (en) * | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
US5024843A (en) * | 1989-09-05 | 1991-06-18 | Alza Corporation | Oral hypoglycemic glipizide granulation |
IT1246188B (en) * | 1990-07-27 | 1994-11-16 | Resa Farma | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING INCREASED SPEED OF DISSOLUTION OF THE ACTIVE SUBSTANCE AND COMPOSITIONS OBTAINED. |
GB9022788D0 (en) * | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
IT1251153B (en) * | 1991-08-06 | 1995-05-04 | Vectorpharma Int | SOLID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION HAVING PROHIBITED GASTRIC RESIDENCE |
US5215758A (en) * | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
IL104192A (en) * | 1992-02-17 | 1998-01-04 | Siegfried Ag Pharma | Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient |
US5292534A (en) * | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
IT1255792B (en) * | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF DIHYDROPYRIDINS IN THE FORM OF DRINK |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
BE1006990A5 (en) * | 1993-04-22 | 1995-02-07 | Univ Gent | METHOD AND COMPOSITION TO MAKE AN ACTIVE INGREDIENT IN A solid dosage form. |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
US5543099A (en) * | 1994-09-29 | 1996-08-06 | Hallmark Pharmaceutical, Inc. | Process to manufacture micronized nifedipine granules for sustained release medicaments |
-
1993
- 1993-09-09 US US08/118,924 patent/US5455046A/en not_active Expired - Lifetime
-
1994
- 1994-08-22 IL IL11074494A patent/IL110744A/en not_active IP Right Cessation
- 1994-08-30 DK DK94401925T patent/DK0642785T3/en active
- 1994-08-30 DE DE0642785T patent/DE642785T1/en active Pending
- 1994-08-30 DE DE69428853T patent/DE69428853T2/en not_active Expired - Lifetime
- 1994-08-30 ES ES01104276T patent/ES2254274T3/en not_active Expired - Lifetime
- 1994-08-30 EP EP01104276A patent/EP1101489B1/en not_active Expired - Lifetime
- 1994-08-30 EP EP94401925A patent/EP0642785B1/en not_active Expired - Lifetime
- 1994-08-30 DE DE69434640T patent/DE69434640T2/en not_active Expired - Fee Related
- 1994-08-30 PT PT01104276T patent/PT1101489E/en unknown
- 1994-08-30 ES ES94401925T patent/ES2070810T3/en not_active Expired - Lifetime
- 1994-08-30 AT AT94401925T patent/ATE207742T1/en not_active IP Right Cessation
- 1994-08-30 AT AT01104276T patent/ATE318586T1/en not_active IP Right Cessation
- 1994-08-30 PT PT94401925T patent/PT642785E/en unknown
- 1994-09-08 CA CA002131647A patent/CA2131647C/en not_active Expired - Lifetime
- 1994-09-09 JP JP24076694A patent/JP4077886B2/en not_active Expired - Fee Related
-
1995
- 1995-05-22 US US08/447,236 patent/US5554387A/en not_active Expired - Lifetime
- 1995-05-22 US US08/447,235 patent/US5512297A/en not_active Expired - Lifetime
- 1995-07-31 GR GR950300035T patent/GR950300035T1/en unknown
-
1996
- 1996-05-21 US US08/651,901 patent/US5667801A/en not_active Expired - Lifetime
-
1997
- 1997-04-18 US US08/843,573 patent/US5846563A/en not_active Expired - Lifetime
-
1998
- 1998-12-08 US US09/207,298 patent/US6136343A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689386B2 (en) | 1996-07-08 | 2004-02-10 | Penwest Pharmaceuticals Co. | Sustained release matrix for high-dose insoluble drugs |
Also Published As
Publication number | Publication date |
---|---|
JPH07165615A (en) | 1995-06-27 |
DE642785T1 (en) | 1995-09-28 |
US5512297A (en) | 1996-04-30 |
DE69434640T2 (en) | 2006-08-10 |
US5554387A (en) | 1996-09-10 |
EP0642785A2 (en) | 1995-03-15 |
PT642785E (en) | 2002-02-28 |
EP0642785B1 (en) | 2001-10-31 |
ES2254274T3 (en) | 2006-06-16 |
EP1101489A3 (en) | 2001-09-19 |
US5667801A (en) | 1997-09-16 |
DE69428853T2 (en) | 2002-04-11 |
JP4077886B2 (en) | 2008-04-23 |
IL110744A0 (en) | 1994-08-22 |
US5846563A (en) | 1998-12-08 |
PT1101489E (en) | 2006-05-31 |
ATE207742T1 (en) | 2001-11-15 |
GR950300035T1 (en) | 1995-07-31 |
DE69434640D1 (en) | 2006-04-27 |
DE69428853D1 (en) | 2001-12-06 |
ES2070810T3 (en) | 2001-12-16 |
CA2131647C (en) | 1999-08-10 |
EP1101489B1 (en) | 2006-03-01 |
ATE318586T1 (en) | 2006-03-15 |
EP0642785A3 (en) | 1996-11-06 |
ES2070810T1 (en) | 1995-06-16 |
US6136343A (en) | 2000-10-24 |
US5455046A (en) | 1995-10-03 |
DK0642785T3 (en) | 2001-12-31 |
IL110744A (en) | 1998-12-27 |
EP1101489A2 (en) | 2001-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2131647A1 (en) | Sustained Release Heterodisperse Hydrogel Systems for Insoluble Drugs | |
GR3030732T3 (en) | Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent. | |
AU8046691A (en) | Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer | |
CA2313642A1 (en) | Pharmaceutical hydrogel formulations, drug delivery devices and methods | |
AU6798890A (en) | Controlled release pharmaceutical preparation and method for producing the same | |
AU7534087A (en) | Sustained release pharmaceutical compositions in oral dosage form | |
EP0396425A3 (en) | Extended release pharmaceutical formulations | |
WO2002000193A3 (en) | Multiple stimulus reversible hydrogels | |
CA2171844A1 (en) | Sustained release formulations for 24 hour release of metoprolol | |
FI914607A (en) | PHARMACEUTICAL BLANDING IN GELFORM I EN DISPENSERFOERPACKNING. | |
BR9708772A (en) | "controlled-release pharmaceutical tablets containing a vehicle based on cross-linked amylose and hydroxy propyl methyl cellulose" | |
AU6421594A (en) | High release solid preparation, preparation and use thereof | |
CA2170748A1 (en) | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis | |
AU654175B2 (en) | Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions | |
CA2085871A1 (en) | A controlled release drug dispersion delivery device | |
AU2702188A (en) | Granules based on hydrophilic polymers on which an aqueous formulation, containing one or more active principles, is absorbed | |
GB2305606A (en) | Drug delivery composition for the nasal administration of antiviral agents | |
AU7511694A (en) | Inclusion complexes of racemic ibuproxam and of optically active ibuproxam with cyclodextrin derivatives, process for the preparation thereof, pharmaceutical preparations containing these inclusion complexes or containing optically active s-(+)-ibuproxam, and use thereof | |
CA2099273A1 (en) | Pressure Sensitive Adhesives for Transdermal Absorption Formulations | |
EP0375649A3 (en) | Swelling-controlled oral delivery system for drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140908 |